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Abstract Senescent cells show an altered secretome
profile termed the senescence-associated secretory
phenotype (SASP). There is an increasing body of
evidence that suggests that the accumulation of SASP-
positive senescent cells in humans is partially causal in
the observed shift to a low-level pro-inflammatory
state in aged individuals. This in turn suggests the
SASP as a possible therapeutic target to ameliorate
inflammatory conditions in the elderly, and thus a
better understanding of the signalling pathways
underlying the SASP are required. Prior studies using
the early generation p38 MAPK inhibitor SB203580
indicated that p38 signalling was required for the
SASP. In this study, we extend these observations
using two next-generation p38 inhibitors (UR-13756
and BIRB 796) that have markedly improved
selectivity and specificity compared to SB203580, to
strengthen the evidence that the SASP is p38-depen-
dent in human fibroblasts. BIRB 796 has an efficacy
and toxicity profile that has allowed it to reach Phase
III clinical trials, suggesting its possible use to
suppress the SASP in vivo. We also demonstrate for
the first time a requirement for signalling through the
p38 downstream MK2 kinase in the regulation of the
SASP using two MK2 inhibitors. Finally, we demon-
strate that a commercially-available multiplex cyto-
kine assay technology can be used to detect SASP
components in the conditioned medium of cultured
fibroblasts from both young and elderly donors. This
assay is a high-throughput, multiplex microtitre-based
assay system that is highly sensitive, with very low
sample requirements, allowing it to be used for low-
volume human biological fluids. Our initial studies
using existing multiplex plates form the basis for a
‘‘SASP signature’’ assay that could be used as a high-
throughput system in a clinical study setting. Our
findings therefore provide important steps towards the
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study of, and intervention in, the SASP in human
ageing and age-related disease.
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Introduction
Cellular senescence is defined as a limited and finite
ability of human cells to divide, and becomes evident
through phenotypic changes in morphology, gene
expression, and function (Campisi 1996; Krtolica and
Campisi 2002). Essentially permanent cell-cycle
arrest is the most obvious characteristic of cell
senescence, whereby expression of cell-cycle-in-
hibitors prevents DNA replication or cell cycle
progression (Herbig et al. 2004; Serrano et al. 1997).
Senescence is divided into two broad categories,
replicative and stress-induced senescence, although
this is an operational definition describing how cells
arrive at senescence; irrespective of inducer, senescent
cells are typically very similar in their properties and
behaviour (Toussaint et al. 2002).
Replicative senescence results from the progressive
shortening of telomeres as cells divide throughout life
(Bodnar et al. 1998). When the telomeres become
critically short they trigger a DNA damage response
involving activation of p53, which in turn up-regulates
the cell-cycle-inhibitor p21CDKN1 resulting in cell
cycle arrest and entry into senescence (Vaziri and
Benchimol 1996). Several experimental manipula-
tions such as hyperoxia, hypermitogenic signalling or
oncogene expression can also trigger entry into a
senescence-like state (Blagosklonny 2003; Saretzki
and Von Zglinicki 2002; Shay and Roninson 2004).
These interventions collectively result in the activa-
tion of the stress-induced p38 mitogen-activated
protein kinase (MAPK) through a process known as
stress-induced premature senescence or SIPS (Haq
et al. 2002; Iwasa et al. 2003; Wang et al. 2002;
Toussaint et al. 2000). The p38 MAPK can mediate
cell cycle arrest directly by activating both p53 and
p21CDKN1 (Bulavin et al. 1999; Haq et al. 2002), or
indirectly via the activation of p16INK4A (Deng et al.
2004; Wang et al. 2002). Because telomere dysfunc-
tion is also a stressor that results in activation of p38
(Iwasa et al. 2003), and p38 can activate p53, the two
pathways may act synergistically. This places p38 at a
pivotal position in the induction of cellular
senescence.
Cellular senescence confers an important tumour-
suppressive function (Prieur and Peeper 2008; Krto-
lica and Campisi 2002). However, the gradual accu-
mulation over the life-course of senescent cells with an
altered phenotype also is likely to contribute to age-
related diseases and degeneration (Ovadya and
Krizhanovsky 2014; Burton 2009). This is believed
to be due, at least in part, to the development of what
has been termed the senescence-associated secretory
phenotype or SASP Coppe et al. 2008, 2010, involving
a marked change in gene expression in senescent cells
with increased expression of pro-inflammatory cytoki-
nes (notably IL-6 and IL-8), chemokines, matrix
metalloproteinases, and other proteins that have the
potential to alter the local tissue microenvironment
(Coppe et al. 2010). The SASP does not develop
immediately after a senescence-inducing stimulus, but
once established it can persist for long periods (Coppe
et al. 2008; Rodier et al. 2009).
The SASP can potentially have both deleterious and
beneficial effects, depending upon the biological
context (Freund et al. 2011). Beneficial aspects appear
to include a reinforcement of the anti-tumour cellular
growth arrest (Acosta et al. 2008), a positive contri-
bution to the clearance of senescent cells by the
immune system (Xue et al. 2007), and suppression of
fibrotic scar formation (Krizhanovsky et al. 2008).
Detrimental effects include the promotion of malig-
nant phenotypes of neighbouring cells and accelerated
tumour growth (Coppe et al. 2010; Krtolica et al. 2001;
Gonzalez et al. 2015). Moreover, many SASP factors
are pro-inflammatory, thus the increased accumulation
of senescent cells with age (Herbig et al. 2006;
Jeyapalan et al. 2007) may contribute to the low-level
chronic inflammation that is a hallmark of aged
mammalian tissues, and provides one route whereby
senescent cells can have deleterious effects in the
context of ageing (Brassard et al. 2015; Davis and
Kipling 2006; Freund et al. 2011; Rodier and Campisi
2011). Given the proposed importance of the SASP, an
understanding of its regulation is crucial, particularly
in the context of developing potential future therapies
for ageing processes.
p38 MAPK is necessary and sufficient for the
development of a SASP in cells induced to senesce by
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direct X-ray induced DNA damage or by expression of
oncogenic ras (Freund et al. 2011). Since many
features of senescence result from p38 activation
(Iwasa et al. 2003), the p38 axis is an attractive target
for therapeutic intervention in aspects of human
ageing and age-related degeneration and diseases that
are postulated to be connected to senescence at the
cellular level. In practice, however, p38 MAPK has
not been a straightforward target for drug develop-
ment. The most commonly used inhibitor SB203580 is
unsuitable for in vivo use due to specificity and
toxicity issues (Goldstein et al. 2010). Many p38
inhibitors with better inhibitory properties than
SB203580 (increased potency, better target speci-
ficity) have been used in clinical trials (Force et al.
2004), but their long-term use has revealed numerous
problems, including examples both of lack of efficacy,
and mild liver and CNS toxicity (Goldstein et al.
2010). As such, none have yet been developed into full
therapeutic use.
These difficulties associated with p38 as a drug
target suggest that other approaches should be
explored in parallel. A major target of p38 is the
kinase MK2, which is involved in the induction of the
stress fibres that are characteristic of senescent cells
via phosphorylation of HSP27 (Guay et al. 1997), cell
cycle arrest via phosphorylation of the phosphatases
CDC25B/C leading to the inhibition of cyclin/CDK
complexes (Manke et al. 2005; Kumar et al. 2003), and
the phosphorylation and inactivation of tristetraprolin
(TTP) which results in the stabilisation of mRNAs
encoding many pro-inflammatory factors (Neininger
et al. 2002; Ross et al. 2012; Hitti et al. 2006). These
lines of evidence point to MK2 being a major kinase
involved in cellular senescent phenotypes including,
possibly, the SASP, although the latter has not been
established. This is supported by evidence showing
that TTP knockout mice are hyper-inflammatory
(Taylor et al. 1996), whereas MK2 knockout mice
are inflammation-resistant (Hegen et al. 2006). It is
interesting to note that MK2 knockout mice are viable,
whereas p38 knockout mice do not survive (Ronkina
et al. 2008). This indicates that MK2 is not essential
for organismal survival, which in turn gives hope that
chemical inhibition of MK2 may be less problematic
than inhibition of p38 (Duraisamy et al. 2008).
In this current study, we explore the expression of
the SASP in several strains of human fibroblasts from
individuals of varying ages, and examine the effects of
a range of p38 and MK2 inhibitors to further elucidate
the molecular pathways involved in SASP expression.
We find that cells from both young and old donors
have low background inflammatory profiles but
demonstrate a robust SASP as they approach senes-
cence. We further show that inhibition of either p38
MAPK or MK2 can suppress the SASP.
Materials and methods
Cells and cell growth
Four strains of human primary normal dermal fibrob-
lasts (NDFs) were obtained from the Coriell Cell
Repositories (Camden, NJ, USA) from a range of
elderly and younger individuals with a range of
replicative capabilities (Cristofalo et al. 1998):
AG16409 (donor age 12), AG07719A (donor age
28), AG08433 (donor age 94) and AG11081 (donor
age 79). Cells were cultured at 37 C in a humidified
incubator with 3 % O2 and 5 % CO2, and all medium
was pre-conditioned in the 3 % O2 environment for
1 h prior to use.
For long-term proliferation to replicative senes-
cence, cells were grown in DMEM supplemented with
10 % FCS as previously described (Davis and Kipling
2009). Population doublings (PDs) were calculated
according to the formula: PD = log(Nt/No)/log(2),
where Nt is number of cells harvested and No is the
initial number of cells seeded.
Protein kinase inhibitors
The protein kinase inhibitor SB203580 was obtained
from Tocris Chemical Co. (Bristol, UK). The kinase
inhibitors BIRB 796 and UR-13756 were synthesised
according to (Bagley et al. 2006, 2010). The MK2
inhibitors MK2.III (Anderson et al. 2007) and PF-
3644022 (Mourey et al. 2010) were obtained from
Merck (UK) and Tocris Chemical Co. (Bristol, UK)
respectively.
Conditioned medium collection and SASP assay
Conditioned medium for detecting SASP components
was collected according to (Coppe et al. 2008) with
slight modifications. In brief, 10,000–30,000 prolifer-
ating cells, or 30,000–50,000 senescent cells were
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seeded into 6 well dishes in DMEM containing 10 %
FCS and cultured at 37 C for 4 days. The medium
was then replaced with DMEM containing 0.5 % FCS
and the cells grown for a further 48 h at 37 C. Finally
the medium was replaced with DMEM without FCS
and the cells incubated for 24 h. The resultant
conditioned medium (3 ml) was harvested, snap-
frozen as 0.5 ml aliquots in liquid nitrogen and stored
at -80 C prior to analysis. Final cell numbers were
determined for all samples and analyte values nor-
malised against cell number. This method is the
standard for analyzing SASP components as used in
the literature (Coppe et al. 2008).
The meso scale discovery (MSD) multiplex
immunoassay (K15007B-1) was used for the simulta-
neous detection of SASP components GM-CSF, IL-
1b, Il-6, IL-8, IL-10, TNFa and IFNc in conditioned
medium using a Sector Imager SI-6000 according to
the manufacturer’s instructions. MIP-3a (J151BEB-
1) detection used an MSD singleplex assay. For
ELISA-based detection of IL-6 in conditioned med-
ium, the 96-well microplate Quantikine IL-6 kit
(#D6050 from R&D Systems) was used according to
the manufacturer’s instructions.
For assessing the effects of the various kinase
inhibitors on the SASP the culture medium was
supplemented with the inhibitor dissolved in DMSO,
with the inhibitors being present throughout the
experiment and replaced at each medium change.
The inhibitors used were BIRB 796 (2.5 lM),
SB203580 (2.5 or 10.0 lM), UR-13756 (2.5 lM),
MK2.III (1.0, 2.5 and 5.0 lM) and PF-3644022 (1.0,
2.5 and 5.0 lM): all concentrations given are the final
concentration in the growth medium. For controls an
equivalent volume of the solvent DMSO was added to
the medium at a final concentration of 0.1 % (v/v). The
p38 inhibitors fully inhibit anisomycin-induced p38/
MK2-dependent phosphorylation of HSP27 at these
concentrations (Bagley et al. 2006, 2010; Davis et al.
2005). The MK2 inhibitors are fully inhibitory for
MK2-dependent HSP27 phosphorylation above
2.0 lM (Davis et al. 2013; Bagley et al. 2015).
Detection of senescence-associated b-
galactosidase activity
Endogenous mammalian senescence-associated b-
galactosidase activity (SA-b-gal) was assessed histo-
chemically as described previously (Davis et al. 2003).
The proportion of b-galactosidase positive cells was
assessed in a total count of 500 cells per sample.
BrdU incorporation assays
Cells were seeded into 6-well dishes cultured for 48 h
in DMEM containing 10 % FCS, and then incubated
in the presence of bromodeoxyuridine (BrdU) at
10 lM for 2 h. After incubation cells were processed
prior to BrdU detection as described (Davis et al.
2005). BrdU incorporation was detected by overnight
incubation with a monoclonal rat anti-BrdU antibody
labelled with fluorescein isothiocyanate (Abcam,
ab74545) with DNA counterstained with DAPI.
Images were captured using fluorescent microscopy
using a Zeiss Axiovert 135 M microscope, and the
BrdU labelling index was calculated as (labelled
cells/total cells) 9 100 %.
Results
Detection of the SASP in replicatively senescent
cells
To determine whether the SASP is related to donor
age, and whether it can be equally detected in
senescent cells from young and old donors, we
analysed a panel of 8 proinflammatory cytokines in
conditioned medium from proliferating cells at early
population doublings in culture, and as those cells
reached senescence (as indicated by a loss of BrdU
labelling, accumulation of SA-b-gal staining and
cessation of proliferation—see Table S1). Fibroblast
strains AG16409 (donor age 12) and AG11081 (donor
age 79) were initially studied. SASP components were
measured quantitatively using MSD immunoassays.
Cytokine levels detected were normalised to cell
number and then expressed as pg/ml medium per
30,000 cells. The levels of each of the eight cytokines
were plotted as a function of cumulative population
doublings: the cytokine levels remained low until the
cells were very close to, or at, replicative senescence,
at which point the levels rose sharply (Fig. 1a).
The data for each cytokine at each PD point were
calculated as a percentage of the maximal level seen at
senescence and then the data were combined to give a
single aggregate ‘‘SASP signature’’ that showed a
large increase when the cells reached replicative
Biogerontology
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Fig. 1 Cytokine levels
versus cumulative
population doublings (CPD)
for AG16409 and AG11081
cells. a Plot of cytokine
levels versus CPD for cell
strains AG16409 (top
panels) and AG11081
(middle panels) and each
analyte. Data is plotted as pg
analyte/ml conditioned
medium (normalised to
30,000 cells) versus CPD
achieved. b The data from a
is calculated for each PD
point as a percentage of the
maximum level seen in the
senescent cells for each
analyte. Then the average is
calculated for all eight
cytokines and plotted
against the CPD. The data is
shown as the average
% ± the SE of the means of
each individual analyte
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senescence (Fig. 1b). This is seen clearly in the
AG16409 fibroblast strain (young donor) as the SASP
signal is low and essentially constant up to the
point when the cells are only 6 PD from senescence,
after which the signal increased rapidly with CPD,
with the signal variability also increasing markedly.
The SASP signature appeared to increase at an earlier
stage in the growth curve for the aged donor
AG11081 cells.
To permit easier comparison of the difference
between proliferating and senescent cells in terms of
SASP, we then pooled data from all proliferating cells
and plotted the mean against pooled SASP data from
all senescent cells of the same strain (see Table S1 for
pools) For both cell lines, the cytokine levels were
higher in medium from the senescent cell populations
compared to the medium taken from proliferating cells
(Fig. 2). In addition, both the 12 year old donor
(AG16409) and the 79 year old donor (AG11081)
cells secreted similar patterns and concentrations of
cytokines (with the possible exception of IL-6). Thus
cells from both young and old donors secrete only low
levels of inflammatory cytokines while they are still
proliferating but both produce a robust SASP once
senescent.
Although we clearly detected a SASP signal using
the MSD immunoassays, the levels of many of the
cytokines on the multiplex plates used were relatively
low. For the remaining part of the study we therefore
focused on IL-6, a canonical surrogate for the SASP,
as it shows a good SASP response in an ELISA based
assay.
To determine whether SASP induction occurs in
cells obtained from both young and old individuals as
they undergo replicative senescence, three Normal
diploid fibroblast strains from donors ranging in age
from twelve to 94 years were cultured continuously
until they reached replicative senescence (defined by
lack of any cell proliferation over at least 30 days, a
BrdU labelling index of less than 4.5 % and SA-b-gal
staining of greater than 80 % (see Table S2 for
details)). Proliferating (low CPD) AG16409A fibrob-
lasts from the youngest donor expressed low levels of
IL-6 (2.66 pg/ml) (Fig. 3), which increased to
46.16 pg/ml when the cells reached senescence,
confirming a robust induction of the IL-6 component
of the SASP. The strain from a 28 year old individual,
AG07719A, had much lower IL-6 levels in prolifer-
ating cells (1.34 pg/ml) that were also elevated in
senescent cells (5.7 pg/ml). Similar results, though
with a much greater fold IL-6 induction, were seen for
the strain AG08433 from a 94 year old individual with
IL-6 levels at 2.6 pg/ml for proliferating low CPD
cells, increasing to 40.04 pg/ml for senescent cells
(Fig. 3b; see also Table S3). Our results clearly show
that fibroblasts from old donors do not secrete high
levels of IL-6 until senescence but then produce a
robust SASP; this is a highly important finding as
Fig. 2 Bar chart showing
cytokine levels in pg/ml
medium for pre-senescent
and senescent AG16409 and
AG11081 cells. The protein
levels are normalised to
30,000 cells (see Table S1
for cell CPD details)
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clinical use of drugs to alleviate SASP in senescence is
likely to focus on elderly patients.
Suppression of the SASP using p38 inhibitors
To test whether inhibition of the p38MAPK signalling
axis impacts on the SASP, proliferating and senescent
fibroblasts were then treated with various inhibitors of
p38 MAPK or MK2 (see Fig. 3; Table S3) and
conditionedmedium tested for IL-6 levels (normalised
to the cell number and expressed as pg/ml medium per
30,000 cells). We find that inhibition of p38 MAPK
reduced senescence-associated IL-6 secretion in all
three cell strains (Table S3; Fig. 3), though variation
between cell strains was observed e.g. in AG16409A
cells IL-6 levels are only reduced to about 40 % of that
seen in senescent cells (Fig. 3b, c), while for AG08433
cells IL-6 levels were reduced by more than 80 %. In
addition, within each cell strain, all three p38
inhibitors tested showed similar efficacy in IL-6
suppression. Finally, as the levels of IL-6 vary
considerably between cell strains and the effects of
the inhibitors are also variable dependent upon strain
used, we repeated the experiment using proliferating
and senescent AG16409 cells using four different
samples as a test of reproducibility (Fig. 3d). As can
be seen, a robust SASP is seen at senescence (as
measured by the increase in IL-6) that is supressed
Fig. 3 Effects of p38 and MK2 inhibitors on IL-6 expression.
Levels of IL-6 in pg/ml conditioned medium (normalised to
30,000 cells) for a AG07719A cells, b AG16409 and AG08433
cells. c Data from a and b expressed as a percentage of IL-6 at
senescence for each strain. d Average IL-6 levels shown as a
percentage of the level seen at senescence for AG16409 cells
using four biological replicates. Only one inhibitor concentra-
tion has been used. Values are mean ± SD, p values are
compared to the levels seen at senescence; Student t Test. Prolif
and sen refer to cells at low CPD and senescence respectively
(see Table S2 for cell CPD details). The rest of the data refer to
inhibitor-treated senescent cells. Key to inhibitors on x axes:
SB = SB203580, UR = UR-13756, B = BIRB 796, PF = PF-
3644022, MK = MK2.III; the numerical values are lM. ND is
not determined
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using a variety of inhibitors with very high repro-
ducibility (as indicated by the p values).
Suppression of the SASP using MK2 inhibitors
We next determined the role of MK2 in IL-6 induction
at senescence. For this we used two commercially
available MK2 inhibitors, PF-3644022 and MK2.III,
both used at a range of concentrations. The effects of
the two inhibitors were cell strain dependent
(Table S3). For AG07719A cells, PF-3644022 had
no effect on IL-6 levels when used at 5 lM, but
reduced IL-6 levels slightly when used at 1.0 and
2.5 lM (Fig. 3a). For strain AG16409A, however, PF-
3644022 treatment (at 1.0 and 2.5 lM) decreased IL-6
levels in senescent cells to almost to the level seen in
young cells (Fig. 3b, c), albeit being less effective at
5.0 lM. The magnitude of the effects of PF-3644022
were smaller in AG08433, the strain from the elderly
individual (Fig. 3b, c), but showed similar trends to
that seen in strain AG016409A from the young donor.
By contrast, MK2.III at 5 lM progressively reduced
secreted IL-6 levels to essentially zero in AG07719A
cells, and to about 25 % of that seen in proliferating
cells for AG16409A and AG08433 cells (Fig. 3a–c).
This MK2 inhibitor was therefore at least as effective
as the p38 inhibitors in IL-6 suppression in all three
strains (Fig. 3c). Thus IL-6 secretion by senescent
cells can be suppressed by inhibition of the MK2
kinase in cells from both young and old donors.
Discussion
There is an increasing body of evidence that suggests
that the accumulation of senescent cells with age in
humans is at least partially causal in the well-observed
shift to a low-level pro-inflammatory state (Freund
et al. 2011; Rodier and Campisi 2011; Burton 2009).
Although definitive proof of the source of these
cytokines has yet to be obtained, there is certainly a
plausible argument for them making a contribution to
age-related diseases and degenerations, many of
which have inflammation as known risk factors. To
explore this further and potentially exploit these
findings in a translational setting requires methodol-
ogy suitable for the detection of SASP analytes in
human clinical material, potentially as part of a large
cohort study, together with drugs suitable for human
clinical trials. This would then open the way to
considering potential human clinical trials of short-
term effect of drug inhibition of the SASP by
measuring circulating pro-inflammatory cytokines in
the elderly (or in human premature ageing syndromes
such asWerner Syndrome, which are associated with a
marked activation of the SASP-regulating p38 MAPK
pathway), and then follow-on work to assess the
physiological and clinical outcomes (Davis and
Kipling 2006).
In the first part of this current study (Fig. 1) we
demonstrate that commercially available multiplex
cytokine assay technology (MSD) can be used to
detect SASP components in the conditioned medium
of cultured fibroblasts from both young and elderly
donors. We note that many laboratory studies on the
SASP use fibroblast strains from young donors
(Freund et al. 2011; Coppe et al. 2008, 2010). Whilst
these have a long replicative lifespan and therefore
produce a very clear and experimentally tractable dis-
tinction between non-senescent (proliferating) and
senescent (arrested) cells, and a very clear SASP as a
result, we are cognisant that in vivo any human clinical
studies would need to measure SASP generated from
cells in an elderly person. It is therefore important that
our data demonstrate that a SASP is generated by
senescent cells from elderly donors, and that it is a
consequence of cellular senescence not donor age. Our
findings therefore add the novel finding of robust
SASP responses in senescent cells from elderly
individuals to the many reports in the literature that
typically use cells derived from young (often new-
born) individuals.
The MSD platform is a high-throughput, multiplex
microtitre-based assay system. It is designed with a
view to facilitating large-scale population-based
human studies. It is very sensitive, with very low
sample requirements, which enables it to be used for
low-volume human biological fluids. Our initial
studies using existing multiplex MSD plates (Fig. 1a)
are encouraging that this would form the basis for a
‘‘SASP signature’’ assay (Fig. 1b) that could be used
in a clinical study setting. Further work is now needed
to refine the choice of analytes on the MSD multiplex
to give an optimum SASP detection system.
Prior studies had indicated a role for p38 MAPK in
expression of the SASP (Freund et al. 2011), although
the work was limited to the use of the p38 inhibitor
SB203580 that is known to be confounded by
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significant off-target effects (Goldstein et al. 2010). To
strengthen the evidence for a role of p38 MAPK
signalling in regulating the SASP we used two next-
generation p38 inhibitors (UR-13756 and BIRB 796)
that have markedly improved selectivity and specificity
compared to SB203580 (Bain et al. 2007; Mihara et al.
2008). As shown in Fig. 3, both compounds are highly
effective at blocking the SASP in senescent cells when
used at concentrations that are known to inhibit p38
MAPK. These data therefore provide further evidence
that signalling through p38 MAPK is required for the
SASP in human cells. As an aside, we note that BIRB
796 has a efficacy and toxicity profile that has allowed it
to reach Phase III clinical trials for inflammatory
conditions such as Crohn’s disease, rheumatoid arthritis,
ulcerative colitis and psoriasis (Force et al. 2004), which
demonstrates the progress that hasbeenmade in bringing
SASP-suppressive drugs into human clinical use.
There are well-documented problems with the
development of drugs that both target p38 MAPK and
are safe and effective for long-term clinical use
(Goldstein et al. 2010). The repeated issues of toxicity
that have been seen with different p38 inhibitors have
raised the possibility that some toxicity may be an
inevitable effect of inhibiting p38 itself. This idea gains
additional strength when we consider the lethality of
p38 knockout in the mouse, as compared to the viability
of knockouts of the downstream target effector kinase
MK2 (Ronkina et al. 2008). Such considerations have
led to efforts to target MK2, in the hope that by
inhibiting a reduced number of pathways and targets
(compared to the upstream p38 MAPK) this could
generate potential drugs with a better toxicity profile
(Duraisamy et al. 2008). Work on MK2 inhibitors has,
however, faced problems due to the relatively shallow
ATP pocket on the protein, which has presented a
challenge to the synthesis of high specificity MK2
inhibitors (Schlapbach and Huppertz 2009). The new
generation of MK2 inhibitors are exemplified by PF-
3644022 and MK2.III. In our experience (data not
shown) PF can demonstrate adverse effects on cell
viability and phenotype at concentrations not substan-
tially greater than required for full inhibition of MK2,
and it would thus seem likely that at lower concentra-
tions PF-3644022 will nevertheless cause some degree
of stress signalling. MK2.III in contrast shows a much
better toxicity profile, with few obvious adverse effects
on cultured fibroblasts at concentrations sufficient to
maximally inhibit MK2 (data not shown). We therefore
tested these two MK2 inhibitors in parallel to our panel
of p38 inhibitors (SB203580, UR-13756 and BIRB
796) for inhibition of the SASP. PF-3644022 does result
in a degree of SASP suppression, but this effect is
rapidly lost at higher concentrations (5 lM) where in
fact levels of secreted IL-6 can exceed those seen in
untreated senescent cells (Fig. 3). Given our observa-
tions of significant adverse pleiotropic effects of PF at
5 lM it seems plausible that the data for this compound
is a mixture of inhibition of the SASP at low levels,
which is then swamped by non-specific MK2-indepen-
dent stress-induced IL-6 induction at higher PF levels.
In contrast, MK2.III has a much better toxicity profile
on cultured cells, and shows initial inhibition of the
SASP at 1 lM (which is less than the level needed for
full MK2 inhibition), progressing to higher levels of
inhibition with almost 100 % inhibition at 5 lM, at
which concentration MK2.III shows little cell toxicity
(Davis et al. 2013). These data provide support for the
continuing development ofMK2 inhibitors for potential
in vivo use for inflammatory conditions, and perhaps
even for human ageing (Duraisamy et al. 2008).
In summary, this study demonstrates that a SASP can
be detected in senescent cells derived from elderly
donors and that a ‘‘SASP signature’’multiplex assay can
be implemented on a high-throughput system that could
potentially be used for human clinical and population
studies. We provide further evidence by the use of
improved p38 inhibitors that the p38/MK2 axis is
critical in regulating the human SASP. Finally, for the
first time we demonstrate an essential role for the
downstream MK2 kinase in regulation of the SASP.
These data provide important steps towards the study
and intervention in the SASP in human ageing and age-
related disease.
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